Member Info for Hulver

Some interesting points from MasterInvestor webinar this evening - "Investing in the Age of Longevity":

(i) in last two months they are starting to see new investment into biotech and supplement sectors

(ii) closed end funds with investment periods (including LP structures), after several quiet years of not makings new investments will be keen to put committed capital to work before the end of their investment period runs out

(iii) end of session panel speakers, representing funds and family offices with $100ms to invest, all very excited about the deals they expect to happen end 2023(!), the array of product candidates due to enter trials in 2024 and fairly optimistic for 2024 both from investment and scientific progress perspectives

(iv) lots of companies needing to raise money, as increasing number of products coming to clinical trials

(iv) funding environment very difficult but one speaker with a portfolio fo 44 has had only one investee company that has not been able to generate funding required for trials. It was said that those companies with excellent product candidates and very good management teams should be able to obtain funding - and interestingly here the emphasis was on the quality of the management team (hopefully having Prevail on board will help with that aspect for Hemo)

(iv) areas of significant potential for investment 2024 and beyond - tissue engineering

(v) focus should be on improving healthspan, and longevity may be a good outcome from that - no point living longer if that life is not going to be healthy; (or if we just be grumpy!)

For anyone interested there may be a recording on their website at some point.

Invested - because like some other people have also mentioned, I have experienced what AML does to an otherwise, up to diagnosis, very healthy person and how its rapid progression takes their life away within a year; and so I too came across Hemo whilst researching AML. Up to then I did not hold any direct investments.

Invested - because (in a generalised big picture sort of view) my limited understanding and research of Hemo's biotech candidates suggests to me that CDX, CAR-T and CBR are all working with nature's principles and encouraging/re-enabling the bodies immune cells to do what they are there to do in nature, so, when re-enabled that's what they do and the disease will be cured or significantly reduced; and therefore I think this type of approach seems to be a plausible pathway towards future success in treating these diseases.

Invested - in Hemo - because I've noticed that often in science there is a discovery that others then use and build on for years to come and which has wide ranging future applications eg x-rate crystallography (WHB and WLB). I think it is possible that VMS's 'significant discovery that the cells that give rise to blood stem cells during mammalian development continue to exist after birth' may be such a discovery - one which may open the door to a fountain of biotech solutions (over a long period of time).

Invested - because potentially a great story is unfolding; and at the same time it's an education.

Advert 4 days ago from Dr Koen van Besien (equity interest in HEMO) head of the Seidman Cancer Centre at University Hospitals, Cleveland and the HEMO advisor that suggested to Vlad (several years ago) that he needed to look at AML as the FLT-3 protein that HEMO's research was targeting for BMT was also pronounced in AML:

https://www.youtube.com/watch?v=oX4X6fWuIRk

After decades of work, he advises that the status nowadays is:

'there's hope for practically every patient'

'...you see them a year later, two years later, and they are cured'

I hope he is prepped ready for HEMO CAR-T trials at UH. Let's hope they have agreed terms to get this done, alongside the trial UPenn.

Pretty sure this happened at least once previously too.

Don't think it's anything more than website fee not paid on time - someone on the admin side not doing their job (again!)

It was our 8th anniversary of our Listing on Thursday (09/11/16).

Didn't anyone else think that with just over 48 hours on the timer - this was HEMO indicating that CAR-T expansion time (if that's the right term) has been cut from the previous couple of weeks down to the targeted few days (ready for the HEMO CAR-T trial)? From the audio it suggests that whatever process it was had just started.

Re the next Funding, let's not forget

Prevail news item reported that they had invested as part of HEMO's PIPE funding round. To me that implies other investors already lined up as part of that PIPE funding round; to be announced when and conditional upon the clinical hold being lifted. Will they be coming in at or around the same price as Prevail; possibly - but then Prevail is getting its investment back through the Phase 1 clinical trial payment they will receive.

As part of Prevail's due diligence they would surely have asked for letters of intent/commitment from other parties in the PIPE funding round. I don't see this fund raise as an issue/concern.

HH, that was Haywain's work and whom you were thanking; not mine

I've had nothing to post for a couple of weeks; I'm still here patiently waiting.

So someone taking these is what has supported the share price these last few trading days?

Closing shorts perhaps or just getting in before the PIPE fully announced?

I guess that if Vlad had time to undertake an interview re Prevail's involvement this is what he might say (courtesy of BriaCell):

https://www.youtube.com/watch?v=K-freayAMOk&t=0s

and the longer version for those more patient:

https://www.youtube.com/watch?v=oQDxN5poaSg&t=18s

Perhaps we should follow their investment strategy.

So Dr Alan Walts has not been heard of or mentioned anywhere by HEMO since his appointment.

Yet all of a sudden there he is on the right hand side of the second slide of the BAIT Biotechnology presenation.

Perhaps all along he has been working on the fund raising/new investors who will join as shareholders in BAIT Biotechnology.

Yes it's us - the same logo is used in the presentation (top right of the first slide)

reposting the presentation link below as it got buried in the detritus on this board

https://www.youtube.com/watch?v=X8tYUMq1Oo0

Well very similar in format, with the Bio vertical - at that time they possibly hadn't finalised it:

Here's the Rest Boston pitchers list.

https://blog.lifesciencenation.com/2023/08/24/view-the-50-companies-pitching-at-resi-boston-september-2023/

And this with the same logo as in presentation:

https://baitbio.com

someone working on something methinks.

Http://baitbiotechnology.com

Working on CBR - might suggest CAR-T work is complete and IND re-submitted?

From the RESI Boston slides:

(i) Dr Alan Walts still involved, which in theory should aid in obtaining private equity investment.

(ii) confirmation that Andrew Wright continues financial controller; though company secretarial role has moved to Ben Harber (of Shakespeare Martineau LLP).

From the CBR patent:

(i) (and this I really like) Michael Haugbro named in the list of inventors, alongside the earlier HEMO scientists. In the HEMO 2023 video he said that he had already been able to contribute. Bait-trap technology was part of field of research at Princeton. Great addition to the team - just over two years at Hemo.

(ii) Former employees Carina Sirochinsky and Raymond Liang also named, so presumably CBR builds upon discoveries/technologies made in the development of CDX.

Never doubted it - I have always thought that this could be a fountain for cures.

Another one added today - may Brian be saved.

Yes, Hemogenyx in the top corner of first slide and he introduces Hemogenyx the company/people.

When the RESI innovator's pitch was first uncovered - you could click on the Bait Biotechnology badge and it took you to the Hemogenyx website.

A bit of an embarrassment that though really when CBR is not to be found there without digging (in the RNS's, the financial reports and a couple of the more recent media clips).

From xviolet's post it is noted that the link to Hemogenyx website has been removed from that RESI page so clicking on the badge goes nowhere. For the other pitchers clicking on their badge still takes you through to their website.

Similarly, any potential investors looking into today's commotion would have to dig deep to find CBR.

More resources needed.

So, Prevail had all the information they required to be comfortable enough making an investment at 6p.

That surely would have included funding plans (in my opinion private) to complete the Phase I trial, and probably beyond that. In their shoes, I would have been asking to see evidence of that eg letters of commitment from investors for the funding for Phase I (it could be debt or equity or a mix). I think those investors must be lined up already - though until they sign there is no guarantee.

The RNS stated Prevail will own just under 0.96% of the company once the shares are issued (that's tomorrow). To me that suggests that we will not hear of the other investors until we reach IND clearance, when the monies are required.

But the information on CBR in the Report, whilst significant, seemed a little light in detail - so like some others I too think that could be the subject of the next RNS.

Think I read somewhere when researching Prevail (so on a Prevail website/twitter page) that there investment was PART OF Hemo's PIPE Funding Round - presumably for Phase 1 CAR-T.

The Report doesn't deny or confirm that but I'm expecting further announcements when the time comes - there is an amount of shares that the can issue to which shareholders gave consent at last AGM.